Loading
A phase 1/2 trial of Azacitidine, Olverembatinib in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML is a phase 1/2 interventional study registered as NCT04501120 by Ascentage Pharma Group Inc., with 682 participants planned, started 2020-09-28 and due to reach its primary completion in 2028-09. Interventions recorded: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575). Conditions listed: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentage Pharma, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Olverembatinib, Ascentage Pharma.
Shares Olverembatinib, Ascentage Pharma.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Olverembatinib, Ascentage Pharma.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/